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To the Editor:
In a recent issue of Biology of Blood and Marrow
Transplantation, Médiavilla et al. [1] explored incidence,
characteristics, potential risk factors, and consequences of
severe acute hepatotoxicity (SAH) associated with rabbit
antithymocyte globulin (ATG, Thymoglobulin [Genzyme,
Cambridge, MA]). SAH was deﬁned as an aspartate amino-
transferase (AST) and/or alanine aminotransferase (ALT) > 5
times the upper limit of normal (ULN) within 1 week after
administration of ATG. SAH was diagnosed in 55 (26%) pa-
tients. Of these 55 patients, 36 (17%) had 5 to 20  ULN
(grade 3) and 19 (9%) had >20  ULN (grade 4). No delete-
rious impact of SAH on survival, nonrelapse mortality,
relapse, or graft-versus-host disease was reported. Risk fac-
tors were blood systolic pressure < 90 mm Hg during
administration of ATG and 2 previous autologous stem cell
transplantations.
We have used rabbit ATG (Thymoglobulin, Genzyme) for
manyyears andwerenotawareof thisproblem.Thisprompted
us to studySAHassociatedwithATG infusionatour institution.
We studied 176 consecutive patients receiving their ﬁrst
allogeneic stem cell transplantations between 2012 and 2014
who received rabbit ATG as part of the conditioning. In this
cohort of patients, SAH was seen in only 9 patients (5%). All 9
patients had grade 3 toxicity (5 to 20  ULN of AST or ALT)
and no grade 4 toxicity (>20ULN) occurred. Themaximum
median levels of AST and ALT among the 9 SAH patients were
6.6  UNL (range, 3.4 to 17.8) and 8.7  ULN (range, 2.3 to
17.0), respectively. In our material, we found a strong effect of
SAH on survival (34% versus 84% at 1 year, P < .001) and
treatment-relatedmortality (59% versus 9%, P< .001). Causes
of death in the SAH patients were relapse in 1 and infection
in 4. No effect on acute GVHD was seen. However, as only 9
patients developed SAH, this should be interpreted with
caution.
The only factor associated to SAH in our cohort was a
female patient; SAH did not occur in any male patient.
The reason for the discrepancy between Médiavilla et al.
and our study is difﬁcult to speculate, but 1 reason might be
the administration of ATG. For many years, we have ﬁrst
administered a small test dose of 25 mg of ATG the day
before the ﬁrst full dose. This procedure has decreased the
number and severity of side effects of ATG at our center. We
give 2mg/kg/day of ATG comparedwith 2.5mg/kg/day in the
French study. Furthermore, our patients receive premed-
ication with antihistamine (klemastin) and methylprednis-
olone (500 mg þ 250 mg) before infusion of ATG to reduce
side effects.
In our opinion, liver toxicity during or within 1 week
after conditioning is mainly due to the conditioning itself
(busulfan) or other drugs given simultaneously, eg, cip-
roﬂoxacin, ﬂuconazole etc. Most patients (n ¼ 6, 67%)
with SAH in our study received busulfan-based reduced-
intensity conditioning. Furthermore, we practice dose
adjustment of busulfan based on pharmacokinetic anal-
ysis in all patients (reduced and myeloablative condi-
tioning), and patients with high busulfan concentrations
are treated with acetylcysteine. With these strategies,
liver toxicity is a rare event at our center and during the
last 5 years, only 1 patient developed liver sinusoidal
obstruction syndrome after busulfan and cyclophospha-
mide conditioning.
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To the Editor:
We read with interest the excellent review of Al-Malki
et al. on hematopoietic stem cell transplantation (HSCT)
for plasmablastic lymphoma (PBL) [1]. The authors con-
clude that autologous HSCT (autoHSCT) might be beneﬁ-
cial both in the salvage setting and for consolidation
of ﬁrst-line responses in this orphan lymphoma subset,
which has a very poor prognosis with conventional
chemotherapy [2]. As this suggestion is largely based
on anecdotal data, we would like to substantiate the
evidence supporting autoHSCT in PBL by reporting the
European Society for Blood and Marrow Transplantation
experience.
Between 2001 and 2011, data pertaining to 24 patients,
who underwent autoHSCT for PBL and had a full MED-A
(minimal essential dataset A) available were reported
to the European Society for Blood and Marrow Trans-
plantation registry. The patient population showed a male
predominance (75%) and a relatively young age (median,
43 years; range, 16 to 63), typical for PBL [2]. The majority
of transplantations were performed in ﬁrst complete
(50%) or partial (17%) remission, and in 71% of the
patients BEAM (carmustine, etoposide, ara-C, melphalan)
or modiﬁcations of BEAM were used as a myeloablative
regimen. Human immune deﬁciency virus (HIV) status
was available for only 8 patients and was positive in 7
of them.
Of the 24 patients, 7 relapsed after autoHSCT, translating
into a 2-year relapse rate of 30% (95% conﬁdence interval [CI],
8% to 57%). In these 7 patients, disease status at HSCT was
ﬁrst complete remission (CR) in 2, ﬁrst partial remission in 2,
third partial remission in 1, and refractory disease in 2 pa-
tients. Notably, no relapse was observed beyond 4 months
from transplantation. Except a single patient who was lost to
follow-up, all relapsed patients subsequently died, most of
them within a short time period after disease recurrence. In
addition, there were 3 nonrelapse deaths (1 from sepsis, 1
from progressive HIV infection, and 1 from a secondary T cell
lymphoma), translating into a 2-year overall survival prob-
ability of 53% (95% CI, 28% to 73%). Patients who were auto-
grafted in CR had a signiﬁcantly lower relapse risk (hazard
ratio, 11.7; 95% CI, 1.98 to 68.9) and overall mortality risk
(hazard ratio, 15.6; 95% CI, 2.62 to 92.5) than more advanced
patients. In contrast, neither age, gender, interval from
diagnosis to autoHSCT, performance status, high-dose
regimen, nor calendar year of transplantation had a signiﬁ-
cant impact on survival.
Limitations of this analysis consist in its retrospective
character, the small sample size, a paucity of information
about pretransplantation treatment, and the median follow-
up of survivors, which was only 30 months (range, 3
to 132; interquartile range, 3 to 63). However, as there
were 11 patients who remained relapse free and survived
6 months or longer, our series supports the notion that
autoHSCT might have the potential to induce sustained
remissions in PBL given the extremely short interval to
disease recurrence in all patients who experienced post-
transplantation relapse. This implies that there is a ratio-
nale to consider autoHSCT as soon as a ﬁrst CR is
achieved. In conclusion, in the absence of effective treat-
ment alternatives, autoHSCT deserves to be further explored
as consolidation for ﬁrst-line and salvage therapy of PBL
both in the HIVþ and HIV setting [3].
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